149 related articles for article (PubMed ID: 35217802)
21. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
22. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
23. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
24. Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
Ren M; Orozco A; Shao K; Albanez A; Ortiz J; Cao B; Wang L; Barreda L; Alvarez CS; Garland L; Wu D; Chung CC; Wang J; Frone M; Ralon S; Argueta V; Orozco R; Gharzouzi E; Dean M
Breast Cancer Res Treat; 2021 Sep; 189(2):533-539. PubMed ID: 34196900
[TBL] [Abstract][Full Text] [Related]
25. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S
Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482
[TBL] [Abstract][Full Text] [Related]
26. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
[TBL] [Abstract][Full Text] [Related]
27. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
28. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.
Cecener G; Egeli U; Tunca B; Erturk E; Ak S; Gokgoz S; Tasdelen I; Tezcan G; Demirdogen E; Bayram N; Avci N; Evrensel T
Cancer Invest; 2014 Oct; 32(8):375-87. PubMed ID: 24884828
[TBL] [Abstract][Full Text] [Related]
29. Identification of Recurrent Variants in
Jiang Y; Tian T; Yu C; Zhou W; Yang J; Wang Y; Wen Y; Chen J; Dai J; Jin G; Ma H; Shen H; Hu Z
Biomed Res Int; 2020; 2020():6739823. PubMed ID: 32879886
[No Abstract] [Full Text] [Related]
30. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
[TBL] [Abstract][Full Text] [Related]
31. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
This P; de la Rochefordière A; Savignoni A; Falcou MC; Tardivon A; Thibault F; Alran S; Fourchotte V; Fitoussi A; Couturaud B; Dolbeault S; Salmon RJ; Sigal-Zafrani B; Asselain B; Stoppa-Lyonnet D;
Fam Cancer; 2012 Sep; 11(3):473-82. PubMed ID: 22711610
[TBL] [Abstract][Full Text] [Related]
32. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
34. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
35. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations.
Caiata-Zufferey M; Pagani O; Cina V; Membrez V; Taborelli M; Unger S; Murphy A; Monnerat C; Chappuis PO
Genet Med; 2015 Sep; 17(9):726-32. PubMed ID: 25503500
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
Torres D; Bermejo JL; Rashid MU; Briceño I; Gil F; Beltran A; Ariza V; Hamann U
Sci Rep; 2017 Jul; 7(1):4713. PubMed ID: 28680148
[TBL] [Abstract][Full Text] [Related]
37. Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer.
Henouda S; Bensalem A; Reggad R; Serrar N; Rouabah L; Pujol P
Dis Markers; 2016; 2016():7869095. PubMed ID: 26997744
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
[TBL] [Abstract][Full Text] [Related]
39. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
West AH; Knollman H; Dugan J; Hedeker D; Handorf EA; Nielsen SM; Bealin LC; Goldblatt LG; Willems H; Daly MB; Afghahi A; Olopade OI; Hulick PJ; Shagisultanova E; Huo D; Obeid E; Churpek JE
Cancer Med; 2019 Sep; 8(12):5609-5618. PubMed ID: 31407530
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]